



## **Absci to Participate on Synthetic Biology Enabling Drug Discovery Panel at Cowen 42nd Annual Health Care Conference**

March 1, 2022

VANCOUVER, Wash., March 01, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced that Sean McClain, CEO & Founder, will be participating on the *Synthetic Biology Enabling Drug Discovery Panel* at the Cowen 42<sup>nd</sup> Annual Health Care Conference.

The panel is scheduled to take place on March 8<sup>th</sup>, 2022 at 12:30-1:30 p.m. Pacific Time / 3:30-4:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the company's investor relations website at: [investors.absci.com](https://investors.absci.com).

### **About Absci**

Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including those that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by *Translating Ideas into Drugs™*. For more information visit [www.absci.com](https://www.absci.com), follow us on social media: Twitter: [@Abscibio](https://twitter.com/Abscibio), LinkedIn: [@absci](https://www.linkedin.com/company/absci), and subscribe to our Absci [YouTube channel](#).

### **Availability of Other Information about Absci**

Investors and others should note that we routinely communicate with investors and the public using our website ([www.absci.com](https://www.absci.com)) and our investor relations website ([investors.absci.com](https://investors.absci.com)), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites. The information that we post on these websites could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website, or any other website that may be accessed from our website, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

### **Investor Contact**

[investors@absci.com](mailto:investors@absci.com)

### **Media Contact**

[press@absci.com](mailto:press@absci.com)